BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million

Reuters03-10

BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million

BioNTech reported Q4 2025 revenue of EUR 907.4 million, down 24%, citing lower COVID-19 vaccine sales due to reduced market demand. Q4 net loss was EUR 305 million, or EUR 1.25 per share, compared with net profit a year earlier. For FY 2025, revenue rose 5% to EUR 2.87 billion, driven by collaboration revenue from Bristol Myers Squibb recognized in Q3. FY net loss widened to EUR 1.14 billion, while cash, cash equivalents and security investments totaled EUR 17.24 billion at year-end. For 2026, BioNTech forecast revenue of EUR 2-2.3 billion and guided for adjusted R&D expenses of EUR 2.2-2.5 billion, as it plans to have eight global Phase 3 trials for PD-L1/VEGF-A bispecific pumitamig ongoing by year-end with Bristol Myers Squibb.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100645PRIMZONEFULLFEED1001169239) on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618893149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618893149","market":"nz","top_or_hot":-1,"title":"BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioNTech reported Q4 2025 revenue of EUR 907.4 million, down 24%, citing lower COVID-19 vaccine sales due to reduced market demand. Q4 net loss was EUR 305 million, or EUR 1.25 per share, compared with net profit a year earlier. For FY 2025, revenue rose 5% to EUR 2.87 billion, driven by collaboration revenue from Bristol Myers Squibb recognized in Q3. FY net loss widened to EUR 1.14 billion, while cash, cash equivalents and security investments totaled EUR 17.24 billion at year-end. For 2026, BioNTech forecast revenue of EUR 2-2.3 billion and guided for adjusted R&amp;D expenses of EUR 2.2-2.5 billion, as it plans to have eight global Phase 3 trials for PD-L1/VEGF-A bispecific pumitamig ongoing by year-end with Bristol Myers Squibb.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100645PRIMZONEFULLFEED1001169239) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioNTech reported Q4 2025 revenue of EUR 907.4 million, down 24%, citing lower COVID-19 vaccine sales due to reduced market demand. Q4 net loss was EUR 305 million, or EUR 1.25 per share, compared with net profit a year earlier. For FY 2025, revenue rose 5% to EUR 2.87 billion, driven by collaboration revenue from Bristol Myers Squibb recognized in Q3. FY net loss widened to EUR 1.14 billion, while cash, cash equivalents and security investments totaled EUR 17.24 billion at year-end. For 2026, BioNTech forecast revenue of EUR 2-2.3 billion and guided for adjusted R&amp;D expenses of EUR 2.2-2.5 billion, as it plans to have eight global Phase 3 trials for PD-L1/VEGF-A bispecific pumitamig ongoing by year-end with Bristol Myers Squibb.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100645PRIMZONEFULLFEED1001169239) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL9TqccP:1","article_id":"2618893149","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618893149","pubTimestamp":1773139582,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioNTech reported Q4 2025 revenue of EUR 907.4 million, down 24%, citing lower COVID-19 vaccine sales due to reduced market demand. Q4 net loss was EUR 305 million, or EUR 1.25 per share, compared with net profit a year earlier. For FY 2025, revenue rose 5% to EUR 2.87 billion, driven by collaboration revenue from Bristol Myers Squibb recognized in Q3. FY net loss widened to EUR 1.14 billion, while cash, cash equivalents and security investments totaled EUR 17.24 billion at year-end. For 2026, BioNTech forecast revenue of EUR 2-2.3 billion and guided for adjusted R&D expenses of EUR 2.2-2.5 billion, as it plans to have eight global Phase 3 trials for PD-L1/VEGF-A bispecific pumitamig ongoing by year-end with Bristol Myers Squibb.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BK4112":"金融交易所和数据","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4581":"高盛持仓","BMY":"施贵宝","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","NDAQ":"纳斯达克OMX交易所","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4534":"瑞士信贷持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4535":"淡马锡持仓","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BNTX":"BioNTech SE","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC"},"translate_title":"BioNTech 2025年第四季度净亏损达到3.05亿欧元，收入下降24%至9.074亿欧元","themeId":"55e023d8b9b1e3375a9483dab88b04b2","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BMY":0.9,"BNTX":0.9},"content_text":"BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million\n    \n\n        BioNTech reported Q4 2025 revenue of EUR 907.4 million, down 24%, citing lower COVID-19 vaccine sales due to reduced market demand. Q4 net loss was EUR 305 million, or EUR 1.25 per share, compared with net profit a year earlier. For FY 2025, revenue rose 5% to EUR 2.87 billion, driven by collaboration revenue from Bristol Myers Squibb recognized in Q3. FY net loss widened to EUR 1.14 billion, while cash, cash equivalents and security investments totaled EUR 17.24 billion at year-end. For 2026, BioNTech forecast revenue of EUR 2-2.3 billion and guided for adjusted R&D expenses of EUR 2.2-2.5 billion, as it plans to have eight global Phase 3 trials for PD-L1/VEGF-A bispecific pumitamig ongoing by year-end with Bristol Myers Squibb.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100645PRIMZONEFULLFEED1001169239) on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618893149","isCrawlerRequest":true}